"Nerve Growth Factor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
NERVE GROWTH FACTOR is the first of a series of neurotrophic factors that were found to influence the growth and differentiation of sympathetic and sensory neurons. It is comprised of alpha, beta, and gamma subunits. The beta subunit is responsible for its growth stimulating activity.
Descriptor ID |
D020932
|
MeSH Number(s) |
D12.644.276.860.437 D12.776.467.860.437 D12.776.631.600.437 D23.529.850.437
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Nerve Growth Factor".
Below are MeSH descriptors whose meaning is more specific than "Nerve Growth Factor".
This graph shows the total number of publications written about "Nerve Growth Factor" by people in this website by year, and whether "Nerve Growth Factor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2000 | 0 | 1 | 1 |
2001 | 1 | 0 | 1 |
2003 | 1 | 0 | 1 |
2005 | 1 | 0 | 1 |
2007 | 1 | 0 | 1 |
2012 | 1 | 0 | 1 |
2014 | 1 | 0 | 1 |
2016 | 0 | 3 | 3 |
2017 | 2 | 0 | 2 |
2018 | 0 | 1 | 1 |
2019 | 1 | 0 | 1 |
2020 | 1 | 1 | 2 |
2022 | 1 | 0 | 1 |
2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Nerve Growth Factor" by people in Profiles.
-
Nerve growth factor receptor limits inflammation to promote remodeling and repair of osteoarthritic joints. Nat Commun. 2024 Apr 15; 15(1):3225.
-
Sensory Neuron-Specific Deletion of Tropomyosin Receptor Kinase A (TrkA) in Mice Abolishes Osteoarthritis (OA) Pain via NGF/TrkA Intervention of Peripheral Sensitization. Int J Mol Sci. 2022 Oct 11; 23(20).
-
A new role for matrix metalloproteinase-3 in the NGF metabolic pathway: Proteolysis of mature NGF and sex-specific differences in the continuum of Alzheimer's pathology. Neurobiol Dis. 2021 01; 148:105150.
-
The human brain NGF metabolic pathway is impaired in the pre-clinical and clinical continuum of Alzheimers disease. Mol Psychiatry. 2021 10; 26(10):6023-6037.
-
Nerve growth factor antibody for the treatment of osteoarthritis pain and chronic low-back pain: mechanism of action in the context of efficacy and safety. Pain. 2019 10; 160(10):2210-2220.
-
ISSLS PRIZE IN BASIC SCIENCE 2018: Growth differentiation factor-6 attenuated pro-inflammatory molecular changes in the rabbit anular-puncture model and degenerated disc-induced pain generation in the rat xenograft radiculopathy model. Eur Spine J. 2018 04; 27(4):739-751.
-
Current status of nerve growth factor antibodies for the treatment of osteoarthritis pain. Clin Exp Rheumatol. 2017 Sep-Oct; 35 Suppl 107(5):85-87.
-
Nerve growth factor blockade for the management of osteoarthritis pain: what can we learn from clinical trials and preclinical models? Curr Opin Rheumatol. 2017 01; 29(1):110-118.
-
Emerging Targets for the Management of Osteoarthritis Pain. Curr Osteoporos Rep. 2016 12; 14(6):260-268.
-
PKCd null mutations in a mouse model of osteoarthritis alter osteoarthritic pain independently of joint pathology by augmenting NGF/TrkA-induced axonal outgrowth. Ann Rheum Dis. 2016 Dec; 75(12):2133-2141.